{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:02:42Z","timestamp":1760234562605,"version":"build-2065373602"},"reference-count":95,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Acute myeloid leukemia (AML) is a heterogenous hematopoietic neoplasm with various genetic abnormalities in myeloid stem cells leading to differentiation arrest and accumulation of leukemic cells in bone marrow (BM). The multiple genetic alterations identified in leukemic cells at diagnosis are the mainstay of World Health Organization classification for AML and have important prognostic implications. Recently, understanding of heterogeneous and complicated molecular abnormalities of the disease could lead to the development of novel targeted therapeutic agents. In the past years, gemtuzumab ozogamicin, BCL-2 inhibitors (venetovlax), IDH 1\/2 inhibitors (ivosidenib and enasidenib) FLT3 inhibitors (midostaurin, gilteritinib, and enasidenib), and hedgehog signaling pathway inhibitors (gladegib) have received US Food and Drug Administration (FDA) approval for the treatment of AML. Especially, AML patients with elderly age and\/or significant comorbidities are not currently suitable for intensive chemotherapy. Thus, novel therapeutic planning including the abovementioned target therapies could lead to improve clinical outcomes in the patients. In the review, we will present various important and frequent molecular abnormalities of AML and introduce the targeted agents of AML that received FDA approval based on the previous studies.<\/jats:p>","DOI":"10.3390\/ijms22115789","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T11:33:20Z","timestamp":1622201600000},"page":"5789","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"22","author":[{"given":"Moo-Kon","family":"Song","sequence":"first","affiliation":[{"name":"Department of Hematology-Oncology, Hanyang University Hanmaeum Changwon Hospital, Changwon 51497, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byeong-Bae","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Hanyang University College of Medicine, Hanyang University Seoul Hospital, Seoul 51139, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Eun","family":"Uhm","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Hanyang University College of Medicine, Hanyang University Seoul Hospital, Seoul 51139, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/bjh.14823","article-title":"Acute myeloid leukaemia genomics","volume":"179","author":"Medinger","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/annonc\/mdp309","article-title":"Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006\u20132010","volume":"21","author":"Pulte","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-019-2654-z","article-title":"Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia","volume":"36","author":"Chen","year":"2019","journal-title":"Pharm. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1182\/bloodadvances.2017009829","article-title":"The role of targeted therapy in the management of patients with AML","volume":"1","author":"Perl","year":"2017","journal-title":"Blood Adv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1038\/s41375-020-0806-0","article-title":"Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"34","author":"Herold","year":"2020","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1532\/IJH97.05144","article-title":"Biology of Normal and Acute Myeloid Leukemia Stem Cells","volume":"82","author":"Dick","year":"2005","journal-title":"Int. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/cncr.22233","article-title":"Acute myeloid leukemia: Epidemiology and etiology","volume":"107","author":"Deschler","year":"2006","journal-title":"Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and saturation analysis of cancer genes across 21 tumour types","volume":"505","author":"Lawrence","year":"2014","journal-title":"Nature"},{"key":"ref_13","first-page":"214","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Weisdorf","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/ng.788","article-title":"Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia","volume":"43","author":"Yan","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_20","first-page":"506","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","article-title":"Differential impact of allelic ratio and insertion site in FLT3-ITD\u2013positive AML with respect to allogeneic transplantation","volume":"124","author":"Schlenk","year":"2014","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/bc010021y","article-title":"Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody\u2212Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia","volume":"13","author":"Hamann","year":"2002","journal-title":"Bioconjugate Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood.V96.2.483.014k40_483_490","article-title":"Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2","volume":"96","author":"Paul","year":"2000","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood-2017-09-797712","article-title":"Gemtuzumab ozogamicin for acute myeloid leukemia","volume":"130","author":"Appelbaum","year":"2017","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate","volume":"93","author":"Sievers","year":"1999","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1126\/science.3240341","article-title":"Calicheamicin gamma 1I: An antitumor antibiotic that cleaves double-stranded DNA site specifically","volume":"240","author":"Zein","year":"1988","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Rosen, D.B., Harrington, K.H., Cordeiro, J.A., Leung, L.Y., Putta, S., Lacayo, N., Laszlo, G.S., Gudgeon, C.J., Hogge, D.E., and Hawtin, R.E. (2013). AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0053518"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/sj.leu.2403598","article-title":"CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: Progress in understanding cytotoxicity and potential mechanisms of drug resistance","volume":"19","author":"Linenberger","year":"2004","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1182\/blood-2002-07-2311","article-title":"Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: Role of Chk1 and Chk2 phosphorylation and caspase 3","volume":"101","author":"Amico","year":"2003","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and Safety of Gemtuzumab Ozogamicin in Patients with CD33-Positive Acute Myeloid Leukemia in First Relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of Chemotherapy for Younger Patients with Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of Patients with Acute Myeloblastic Leukemia Who Benefit from the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3324\/haematol.2016.141937","article-title":"Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: A comparison of 3 mg\/m2 with 6 mg\/m2 in the NCRI AML17 Trial","volume":"101","author":"Burnett","year":"2016","journal-title":"Haematology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients with Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1097-2765(01)00320-3","article-title":"BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis","volume":"8","author":"Cheng","year":"2001","journal-title":"Mol. Cell."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax Combined with Low-Dose Cytarabine for Previously Untreated Patients with Acute Myeloid Leukemia: Results from a Phase Ib\/II Study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"Dinardo","year":"2019","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/10428194.2014.910657","article-title":"Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies","volume":"56","author":"Bogenberger","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"91","author":"Tsao","year":"2012","journal-title":"Ann. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"Dinardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/0092-8674(93)90325-K","article-title":"Molecular cloning of a ligand for the flt3\/flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells","volume":"75","author":"Lyman","year":"1993","journal-title":"Cell"},{"key":"ref_48","first-page":"1911","article-title":"Internal tandem duplication of the flt3 gene found in acute myeloid leukemia","volume":"10","author":"Nakao","year":"1996","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","article-title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies","volume":"97","author":"Yamamoto","year":"2001","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.molcel.2009.09.019","article-title":"Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes","volume":"36","author":"Choudhary","year":"2009","journal-title":"Mol. Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2004-07-2942","article-title":"AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations","volume":"106","author":"Choudhary","year":"2005","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"8870","DOI":"10.18632\/oncotarget.22926","article-title":"FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K\/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1\/Mcl-1 pathway","volume":"9","author":"Okada","year":"2017","journal-title":"Oncotarget"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2004-06-2459","article-title":"FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L)","volume":"105","author":"Bagrintseva","year":"2005","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00277-014-2072-6","article-title":"Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: A systematic review and meta-analysis","volume":"93","author":"Port","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1535-6108(02)00069-7","article-title":"Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412","volume":"1","author":"Weisberg","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin approved for FLT3-mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/leu.2012.115","article-title":"Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia","volume":"26","author":"Stone","year":"2012","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2217\/fon.14.105","article-title":"Quizartinib for the treatment of FLT3\/ITD acute myeloid leukemia","volume":"10","author":"Levis","year":"2014","journal-title":"Futur. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1200\/JCO.2013.48.8783","article-title":"Phase I Study of Quizartinib Administered Daily to Patients with Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3\u2013Internal Tandem Duplication Status","volume":"31","author":"Cortes","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1470-2045(18)30240-7","article-title":"Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: An open-label, multicentre, single-arm, phase 2 trial","volume":"19","author":"Cortes","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): A multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2016-10-745133","article-title":"Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor","volume":"129","author":"Lee","year":"2017","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: A multicentre, first-in-human, open-label, phase 1\u20132 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/jnci\/djq187","article-title":"Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism","volume":"102","author":"Reitman","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3389\/fonc.2013.00169","article-title":"The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms","volume":"3","author":"Rakheja","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_70","first-page":"246","article-title":"The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia","volume":"25","author":"Hou","year":"2010","journal-title":"Leukemia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2009-11-253070","article-title":"Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation","volume":"115","author":"Chou","year":"2010","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood-2010-03-272146","article-title":"Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia","volume":"116","author":"Thol","year":"2010","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1182\/blood-2012-06-438267","article-title":"Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response","volume":"120","author":"Fathi","year":"2012","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2009-11-250878","article-title":"Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: Prevalence and prognostic value","volume":"116","author":"Abbas","year":"2010","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/leu.2016.275","article-title":"Isocitrate dehydrogenase mutations in myeloid malignancies","volume":"31","author":"Medeiros","year":"2017","journal-title":"Leukemia"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s40265-018-0978-3","article-title":"Ivosidenib: First Global Approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40265-017-0813-2","article-title":"Enasidenib: First Global Approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/2159-8290.CD-16-1034","article-title":"AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations","volume":"7","author":"Yen","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-140005","article-title":"Real-World Use of Enasidenib in Relapsed or Refractory Acute Myeloid Leukemia Is Associated with Reduced Risk of Disease Progression and Death","volume":"136","author":"Klink","year":"2020","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-141987","article-title":"Enasidenib, an Oral Therapy in Mutant IDH2 Relapsed\/Refractory Acute Myeloid Leukemia: A Real-Life Single Center Experience","volume":"136","author":"Riva","year":"2020","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib inIDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"Dinardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-136957","article-title":"Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls","volume":"136","author":"Paschka","year":"2020","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.stem.2009.03.015","article-title":"Hedgehog Signaling Is Dispensable for Adult Hematopoietic Stem Cell Function","volume":"4","author":"Gao","year":"2009","journal-title":"Cell Stem Cell"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1182\/blood-2011-07-368142","article-title":"Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma","volume":"120","author":"Blotta","year":"2012","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.4161\/cc.9.17.12945","article-title":"Hedgehog pathway activation in chronic myeloid leukemia: A promise for a novel combination therapeutic approach?","volume":"9","author":"Jagani","year":"2010","journal-title":"Cell Cycle"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1158\/1078-0432.CCR-09-2570","article-title":"The role of the hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment","volume":"16","author":"Caro","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1158\/0008-5472.CAN-05-0481","article-title":"Targeting medulloblastoma: Small-molecule inhibitors of the Sonic Hedgehog pathway as potential cancer therapeutics","volume":"65","author":"Romer","year":"2005","journal-title":"Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ccr.2014.01.008","article-title":"The PRKCI and SOX2 Oncogenes Are Coamplified and Cooperate to Activate Hedgehog Signaling in Lung Squamous Cell Carcinoma","volume":"25","author":"Justilien","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/B978-0-12-394622-5.00002-X","article-title":"Canonical and noncanonical Hedgehog\/GLI signaling in hematological malignancies","volume":"88","author":"Aberger","year":"2012","journal-title":"Vitam. Horm."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1046\/j.1523-1747.1998.00222.x","article-title":"Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome","volume":"110","author":"Aszterbaum","year":"1998","journal-title":"J. Invest Dermatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/cas.13019","article-title":"Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells","volume":"107","author":"Fukushima","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-015-0453-9","article-title":"GLI2 inhibition abrogates human leukemia stem cell dormancy","volume":"13","author":"Sadarangani","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/11\/5789\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:10:06Z","timestamp":1760163006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/11\/5789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":95,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["ijms22115789"],"URL":"https:\/\/doi.org\/10.3390\/ijms22115789","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2021,5,28]]}}}